Zhonghua Zhong Liu Za Zhi. 2016 Apr;38(4):310-20. doi: 10.3760/cma.j.issn.0253-3766.2016.04.013.
Soft tissue sarcoma is a group of malignancies of mesenchymal origin. It arises from almost every part of human body in all decades. Appropriate dagnosis and treatment of soft tissue sarcoma are always challenging to physicians and pathologists because of its extremely low incidence and variable biological behaviors among subtypes. Surgical resection remains the most important and only method to cure soft tissue sarcomas, while chemoradiation and target therapy are incorporated into multidisciplinary treatment model, but there is no generally accepted consensus on how to do multidisciplinary treatment properly and maximize the therapeutic effects. The aim of this article is to improve the understanding of multidisciplinary treatment of soft tissue sarcomas and to provide a guidance nationwide based on evidence-based medicine and expert's experience on related topics.
软组织肉瘤是一组间叶组织来源的恶性肿瘤。它在各个年龄段都可发生于人体几乎每个部位。由于软组织肉瘤发病率极低且各亚型生物学行为各异,其准确诊断和治疗一直是医生和病理学家面临的挑战。手术切除仍然是治愈软组织肉瘤最重要且唯一的方法,同时放化疗和靶向治疗也被纳入多学科治疗模式,但对于如何恰当地进行多学科治疗以及最大化治疗效果,目前尚无普遍认可的共识。本文旨在增进对软组织肉瘤多学科治疗的理解,并基于循证医学和专家在相关主题上的经验提供全国性的指导。